Intralesional Bleomycin Sclerotherapy of Lymphangiomas in Children: Our Initial Experience

Denis Žigić, Amir Halilbašić, Edin Husarić, Nešad Hotić, Sanimir Suljendić, Emir Rahmanović


Objective − We report our initial experience with intralesional bleomycin sclerotherapy of macrocystic lymphangiomas in three pediatric patients.

Case Reports − Case 1. A 3.5-month-old male child presented to our institution with a radiologically verified macrocystic lymphangioma of the left thoracoabdominal region. After 2 cycles of sclerotherapy complete regression of the tumefact was achieved. Case 2. A 23-month-old male child presented with a radiologically confirmed lymphangioma in the sternal region. In total, he underwent 6 cycles of sclerotherapy in about 7 months. At first there was no response to therapy, but after the last cycle, the end result was excellent. Case 3. A 2-month-old male child presented with a radiologically confirmed lymphangioma of the left axillary region. He underwent 4 cycles of sclerotherapy in 4 months. The end result was excellent - complete regression of the tumefact.

Conclusion – In all our cases, intralesional bleomycin sclerotherapy was successful alone and showed very good end results. There were no serious side effects in any of our cases. Therefore, bleomycin is a safe alternative to surgical treatment of lymphangiomas in the pediatric population.


Bleomycin; Lymphatic Malformations; Sclerotherapy

Full Text:




  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

The full text of articles published in this journal can be used free of charge for personal and educational purposes while respecting authors and publishers' copyrights. For commercial purposes no part of this journal may be reproduced without the written permission of the publisher.